Compare

X4 Pharmaceuticals/$XFOR

1D1W1M3M6MYTD1Y5YMAX

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Ticker
$XFOR
Sector
Health
Primary listing
NASDAQ
Employees
45
Headquarters
Boston, United States
Website
www.x4pharma.com

XFOR Metrics

BasicAdvanced
$304M
-
-$0.66
-
-

Bulls say / Bears say

The European Commission authorised XOLREMDI for WHIM syndrome, giving the drug the first and only authorised treatment position in the EU. Norgine will commercialise it there, while X4 is eligible for milestone payments and royalties on sales. (X4 Pharmaceuticals)
The FDA agreed that X4 can reduce the 4WARD trial from 176 to 126 participants while retaining adequate power for both main measures, and said the proposed safety database could support a filing. This makes the pivotal study more manageable without an agreed reduction in its statistical strength. (X4 Pharmaceuticals)
X4 reported $208 million in cash and short-term investments at the end of June and expects its cash runway to extend into 2029. That gives it funding to advance the pivotal trial and prepare for a potential launch without an immediate need to raise capital. (X4 Pharmaceuticals)
US product sales were only $2.4 million in the second quarter, while X4 used $40.4 million of cash in operating activities in the first half. The company says product and licensing income will not cover operating costs, leaving it dependent on financing until sales grow substantially. (SEC)
The 4WARD trial is not expected to report topline results until the first half of 2028, even with the reduced enrolment target. Investors face an extended wait for a pivotal result, and the trial still has to show benefit on both main measures. (X4 Pharmaceuticals)
The new $80 million loan was used largely to repay the previous facility, while access to a further $70 million depends on lender approval. The financing therefore leaves X4 with substantial secured debt and no certainty that the extra borrowing will be available if needed. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.

XFOR Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

XFOR Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

XFOR News

AllArticlesVideos

4 Biotech Stocks Seeing Unusual Options Volume Today

Schaeffers Research3 days ago

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

MarketBeat1 week ago

Funds containing XFOR

Funds
Fund name
Fund size
$XFOR weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.